Literature DB >> 16543390

Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology.

Antoon J M Janssen1, Frans J M Trijbels, Rob C A Sengers, Liesbeth T M Wintjes, Wim Ruitenbeek, Jan A M Smeitink, Eva Morava, Baziel G M van Engelen, Lambert P van den Heuvel, Richard J T Rodenburg.   

Abstract

BACKGROUND: Diagnosis of mitochondrial disorders usually requires a muscle biopsy to examine mitochondrial function. We describe our diagnostic procedure and results for 29 patients with mitochondrial disorders.
METHODS: Muscle biopsies were from 43 healthy individuals and 29 patients with defects in one of the oxidative phosphorylation (OXPHOS) complexes, the pyruvate dehydrogenase complex (PDHc), or the adenine nucleotide translocator (ANT). Homogenized muscle samples were used to determine the oxidation rates of radiolabeled pyruvate, malate, and succinate in the absence or presence of various acetyl Co-A donors and acceptors, as well as specific inhibitors of tricarboxylic acid cycle or OXPHOS enzymes. We determined the rate of ATP production from oxidation of pyruvate.
RESULTS: Each defect in the energy-generating system produced a specific combination of substrate oxidation impairments. PDHc deficiencies decreased substrate oxidation reactions containing pyruvate. Defects in complexes I, III, and IV decreased oxidation of pyruvate plus malate, with normal to mildly diminished oxidation of pyruvate plus carnitine. In complex V defects, pyruvate oxidation improved by addition of carbonyl cyanide 3-chlorophenyl hydrazone, whereas other oxidation rates were decreased. In most patients, ATP production was decreased.
CONCLUSION: The proposed method can be successfully applied to the diagnosis of defects in PDHc, OXPHOS complexes, and ANT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543390     DOI: 10.1373/clinchem.2005.062414

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  33 in total

1.  Chronic progressive external ophthalmoplegia caused by an m.4267A > G mutation in the mitochondrial tRNAIle.

Authors:  Bart W Smits; Frans A Hol; Lambert P van den Heuvel; Gea Drost; Richard J T Rodenburg; Henk J Ter Laak; Baziel G M van Engelen
Journal:  J Neurol       Date:  2007-11-02       Impact factor: 4.849

2.  NDUFA2 complex I mutation leads to Leigh disease.

Authors:  Saskia J G Hoefs; Cindy E J Dieteren; Felix Distelmaier; Rolf J R J Janssen; Andrea Epplen; Herman G P Swarts; Marleen Forkink; Richard J Rodenburg; Leo G Nijtmans; Peter H Willems; Jan A M Smeitink; Lambert P van den Heuvel
Journal:  Am J Hum Genet       Date:  2008-06       Impact factor: 11.025

3.  Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia.

Authors:  Steffi van de Ven; Thatjana Gardeitchik; Dorus Kouwenberg; Leo Kluijtmans; Ron Wevers; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2013-10-31       Impact factor: 4.982

4.  A novel mitochondrial ATP8 gene mutation in a patient with apical hypertrophic cardiomyopathy and neuropathy.

Authors:  An I Jonckheere; Marije Hogeveen; Leo Nijtmans; Mariel van den Brand; Antoon Janssen; Heleen Diepstra; Frans van den Brandt; Bert van den Heuvel; Frans Hol; Tom Hofste; Livia Kapusta; U Dillmann; M Shamdeen; J Smeitink; J Smeitink; Richard Rodenburg
Journal:  BMJ Case Rep       Date:  2009-01-23

Review 5.  Neurodevelopmental manifestations of mitochondrial disease.

Authors:  Marni J Falk
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

6.  SDHA mutations causing a multisystem mitochondrial disease: novel mutations and genetic overlap with hereditary tumors.

Authors:  G Herma Renkema; Saskia B Wortmann; Roel J Smeets; Hanka Venselaar; Marion Antoine; Gepke Visser; Tawfeg Ben-Omran; Lambert P van den Heuvel; Henri J L M Timmers; Jan A Smeitink; Richard J T Rodenburg
Journal:  Eur J Hum Genet       Date:  2014-04-30       Impact factor: 4.246

7.  Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy.

Authors:  John F O'Toole; Yangjian Liu; Erica E Davis; Christopher J Westlake; Massimo Attanasio; Edgar A Otto; Dominik Seelow; Gudrun Nurnberg; Christian Becker; Matti Nuutinen; Mikko Kärppä; Jaakko Ignatius; Johanna Uusimaa; Salla Pakanen; Elisa Jaakkola; Lambertus P van den Heuvel; Henry Fehrenbach; Roger Wiggins; Meera Goyal; Weibin Zhou; Matthias T F Wolf; Eric Wise; Juliana Helou; Susan J Allen; Carlos A Murga-Zamalloa; Shazia Ashraf; Moumita Chaki; Saskia Heeringa; Gil Chernin; Bethan E Hoskins; Hassan Chaib; Joseph Gleeson; Takehiro Kusakabe; Takako Suzuki; R Elwyn Isaac; Lynne M Quarmby; Bryan Tennant; Hisashi Fujioka; Hannu Tuominen; Ilmo Hassinen; Hellevi Lohi; Judith L van Houten; Agnes Rotig; John A Sayer; Boris Rolinski; Peter Freisinger; Sethu M Madhavan; Martina Herzer; Florence Madignier; Holger Prokisch; Peter Nurnberg; Peter K Jackson; Peter Jackson; Hemant Khanna; Nicholas Katsanis; Friedhelm Hildebrandt
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

8.  Mutation in subdomain G' of mitochondrial elongation factor G1 is associated with combined OXPHOS deficiency in fibroblasts but not in muscle.

Authors:  Paulien Smits; Hana Antonicka; Peter M van Hasselt; Woranontee Weraarpachai; Wolfram Haller; Marieke Schreurs; Hanka Venselaar; Richard J Rodenburg; Jan A Smeitink; Lambert P van den Heuvel
Journal:  Eur J Hum Genet       Date:  2010-12-01       Impact factor: 4.246

Review 9.  Biochemical diagnosis of mitochondrial disorders.

Authors:  Richard J T Rodenburg
Journal:  J Inherit Metab Dis       Date:  2010-05-04       Impact factor: 4.982

10.  Normal biochemical analysis of the oxidative phosphorylation (OXPHOS) system in a child with POLG mutations: a cautionary note.

Authors:  M C de Vries; R J Rodenburg; E Morava; M Lammens; L P W van den Heuvel; G Christoph Korenke; J A M Smeitink
Journal:  J Inherit Metab Dis       Date:  2008-05-20       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.